FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079083672> ?p ?o ?g. }

• W2079083672 endingPage "C27" @default.
• W2079083672 startingPage "C27" @default.
• W2079083672 abstract "Abstract Background: The benefit of EGFR tyrosine kinase inhibitors (TKIs) is largely restricted to EGFR mutation-positive cancers and resistance invariably develops. A central theme of acquired resistance is persistent ErbB3 signaling, resulting in activation of the PI3K/AKT survival pathway. MM-121 is a fully human IgG1 monoclonal antibody (mAb) to ErbB3 with pre-clinical activity as a single agent and in combination with erlotinib in NSCLC, particularly in cancers with ligand-dependent activation of EGFR. This phase 1 study evaluated the safety and tolerability of MM-121 and erlotinib in NSCLC, as well as PK, immunogenicity, efficacy endpoints and exploratory biomarker evaluation. Methods: Patients with advanced NSCLC, good performance status and adequate organ function were enrolled. Patients were EGFR TKI-naïve, unless they were EGFR mutant, in which case acquired resistance was allowed. MM-121 was administered weekly and erlotinib was administered daily. Seven cohorts were enrolled, evaluating varying dose levels of the combination, as well as alternate MM-121 infusion schedules. Dose levels were determined by safety and pharmacokinetic (PK) data. Results: Between February 2010 and July 2011, 33 patients were enrolled. Median age was 64 years and there were 19 (57.5%) women. Twenty-four patients were erlotinib-naïve and 1 patient was an EGFR mutant. The most frequent adverse events were rash, diarrhea, nausea and fatigue. As of 31 July 2001, 16 patients remain on study. Full results will be presented at the meeting. Conclusions: In this phase 1 dose escalation study, MM-121 plus erlotinib was well tolerated by the majority of patients. A phase 2 study is planned. Reference: NCT00994123 Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C27." @default.
• W2079083672 created "2016-06-24" @default.
• W2079083672 creator A5015122622 @default.
• W2079083672 creator A5030465062 @default.
• W2079083672 creator A5033583599 @default.
• W2079083672 creator A5033724353 @default.
• W2079083672 creator A5035795255 @default.
• W2079083672 creator A5049754609 @default.
• W2079083672 creator A5055791669 @default.
• W2079083672 creator A5059232093 @default.
• W2079083672 creator A5072119182 @default.
• W2079083672 creator A5075333926 @default.
• W2079083672 date "2011-11-01" @default.
• W2079083672 modified "2023-09-27" @default.
• W2079083672 title "Abstract C27: Targeting ErbB3 and EGFR in lung cancer patients: A phase I trial of MM-121 in combination with erlotinib in patients with non-small cell lung cancer (NSCLC)." @default.
• W2079083672 doi "https://doi.org/10.1158/1535-7163.targ-11-c27" @default.
• W2079083672 hasPublicationYear "2011" @default.
• W2079083672 type Work @default.
• W2079083672 sameAs 2079083672 @default.
• W2079083672 citedByCount "2" @default.
• W2079083672 countsByYear W20790836722017 @default.
• W2079083672 crossrefType "journal-article" @default.
• W2079083672 hasAuthorship W2079083672A5015122622 @default.
• W2079083672 hasAuthorship W2079083672A5030465062 @default.
• W2079083672 hasAuthorship W2079083672A5033583599 @default.
• W2079083672 hasAuthorship W2079083672A5033724353 @default.
• W2079083672 hasAuthorship W2079083672A5035795255 @default.
• W2079083672 hasAuthorship W2079083672A5049754609 @default.
• W2079083672 hasAuthorship W2079083672A5055791669 @default.
• W2079083672 hasAuthorship W2079083672A5059232093 @default.
• W2079083672 hasAuthorship W2079083672A5072119182 @default.
• W2079083672 hasAuthorship W2079083672A5075333926 @default.
• W2079083672 hasConcept C115456853 @default.
• W2079083672 hasConcept C121608353 @default.
• W2079083672 hasConcept C126322002 @default.
• W2079083672 hasConcept C143998085 @default.
• W2079083672 hasConcept C197934379 @default.
• W2079083672 hasConcept C2776256026 @default.
• W2079083672 hasConcept C2778087573 @default.
• W2079083672 hasConcept C2778375690 @default.
• W2079083672 hasConcept C2778570526 @default.
• W2079083672 hasConcept C2779438470 @default.
• W2079083672 hasConcept C2780580376 @default.
• W2079083672 hasConcept C2780580887 @default.
• W2079083672 hasConcept C71924100 @default.
• W2079083672 hasConcept C98274493 @default.
• W2079083672 hasConceptScore W2079083672C115456853 @default.
• W2079083672 hasConceptScore W2079083672C121608353 @default.
• W2079083672 hasConceptScore W2079083672C126322002 @default.
• W2079083672 hasConceptScore W2079083672C143998085 @default.
• W2079083672 hasConceptScore W2079083672C197934379 @default.
• W2079083672 hasConceptScore W2079083672C2776256026 @default.
• W2079083672 hasConceptScore W2079083672C2778087573 @default.
• W2079083672 hasConceptScore W2079083672C2778375690 @default.
• W2079083672 hasConceptScore W2079083672C2778570526 @default.
• W2079083672 hasConceptScore W2079083672C2779438470 @default.
• W2079083672 hasConceptScore W2079083672C2780580376 @default.
• W2079083672 hasConceptScore W2079083672C2780580887 @default.
• W2079083672 hasConceptScore W2079083672C71924100 @default.
• W2079083672 hasConceptScore W2079083672C98274493 @default.
• W2079083672 hasIssue "11_Supplement" @default.
• W2079083672 hasLocation W20790836721 @default.
• W2079083672 hasOpenAccess W2079083672 @default.
• W2079083672 hasPrimaryLocation W20790836721 @default.
• W2079083672 hasRelatedWork W1602357875 @default.
• W2079083672 hasRelatedWork W1618072806 @default.
• W2079083672 hasRelatedWork W1824070893 @default.
• W2079083672 hasRelatedWork W2015910003 @default.
• W2079083672 hasRelatedWork W2017389411 @default.
• W2079083672 hasRelatedWork W2060263774 @default.
• W2079083672 hasRelatedWork W2186047679 @default.
• W2079083672 hasRelatedWork W2217699725 @default.
• W2079083672 hasRelatedWork W2888534976 @default.
• W2079083672 hasRelatedWork W2978946191 @default.
• W2079083672 hasVolume "10" @default.
• W2079083672 isParatext "false" @default.
• W2079083672 isRetracted "false" @default.
• W2079083672 magId "2079083672" @default.
• W2079083672 workType "article" @default.